Market Closed - Nyse 04:00:02 2024-03-27 pm EDT 5-day change 1st Jan Change
105.4 USD +1.92% Intraday chart for Revvity, Inc. +0.71% -3.57%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Revvity Files Lawsuit Against Partner Cloud Software Group, Reaffirms 2024 Guidance MT
Revvity, Inc. Re-Affirms Earnings Guidance for the Full Year 2024 CI
Transcript : Revvity, Inc. Presents at KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum, Mar-20-2024 09:00 AM
Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication CI
Revvity, Inc. Introduces New Workflow to Accelerate Newborn Sequencing Research CI
Transcript : Revvity, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 09:30 AM
Transcript : Revvity, Inc. Presents at 45th Annual Raymond James Institutional Investors Conference 2024, Mar-05-2024 09:15 AM
Transcript : Revvity, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-04-2024 09:10 AM
Transcript : Revvity, Inc. Presents at Citi?s 2024 Unplugged Medtech and Life Sciences Access Day, Feb-29-2024 08:00 AM
Revvity Signals Software Unveils Signals Clinical Solution to Accelerate Critical Clinical Trial Insights and Data-Driven Decisions CI
Revvity Insider Sold Shares Worth $3,841,563, According to a Recent SEC Filing MT
Revvity Insider Sold Shares Worth $1,613,697, According to a Recent SEC Filing MT
KeyBanc Ups Price Target on Revvity to $126 From $110, Keeps Overweight Rating MT
Raymond James Raises Price Target on Revvity to $127 From $106, Maintains Outperform Rating MT
Job data is good for the economy, not for rate cuts Our Logo
Revvity Showcases Cutting-Edge Solutions at SLAS2024 CI
ANALYST RECOMMENDATIONS : Alphabet, Meta Platforms, Amazon, Wise, Clorox... Our Logo
Revvity Q4 Adjusted Earnings, Revenue Decline; Issues 2024 Guidance MT
Transcript : Revvity, Inc., Q4 2023 Earnings Call, Feb 01, 2024
Earnings Flash (RVTY) REVVITY Reports Q4 Revenue $695.9M, vs. Street Est of $680M MT
Earnings Flash (RVTY) REVVITY Posts Q4 EPS $1.25, vs. Street Est of $1.16 MT
Revvity, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Revvity, Inc. Provides Revenue Guidance for the Full Year of 2024 CI
BofA Securities Raises Price Target on Revvity to $117 From $104, Maintains Neutral Rating MT
Revvity Keeps Quarterly Dividend at $0.07 a Share, Payable May 10 to Shareholders of Record April 19 MT
Chart Revvity, Inc.
More charts
Revvity, Inc. (formerly PerkinElmer, Inc.) specializes in designing, manufacturing, and marketing measurement devices and analytical instruments for the healthcare, environmental, scientific research, industry and food sectors. Net sales (including intragroup) break down by family of products as follows: - medical diagnosis equipment (61%); - analytical tools and instruments (39%): biological molecular research tools, thermal analysis software, chemical and environmental measurement tools, genetic screening instruments, reagents, etc. Net sales are distributed geographically as follows: the United States (46.7%), China (14.4%), the United Kingdom (4.1%) and other (34.8%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
105.4 USD
Average target price
123.1 USD
Spread / Average Target
+16.79%
Consensus
  1. Stock
  2. Equities
  3. Stock Revvity, Inc. - Nyse
  4. News Revvity, Inc.
  5. PerkinElmer : to Buy BioLegend for $5.25 Billion as Second-Quarter Results Top Street Views, 2021 Guidance Lifted